{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:24:03Z","timestamp":1779362643472,"version":"3.51.4"},"reference-count":67,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains a cornerstone in the treatment of high-risk acute lymphoblastic leukemia (ALL), yet optimal patient selection is challenging in the era of rapidly changing modern therapy. Refined molecular characterization allows for better risk assessment, sparing low-risk patients from allo-HCT toxicity while identifying those who may benefit from intensified approaches. Measurable residual disease (MRD) has emerged as a powerful predictor of relapse irrespective of treatment strategy, challenging the necessity of transplant in MRD-negative patients. Further, expanded donor options, particularly haploidentical transplantation coupled with reduced intensity conditioning, have extended the applicability of allo-HCT to a broader range of patients. Finally, immunotherapies and targeted treatments are increasingly integrated into both initial and relapsed treatment protocols yielding deep remission and allowing for successful transplant in patients with a history of advanced disease. In this review, we provide an overview of the contemporary role of transplant in adult patients with ALL, focusing on indications for allo-HCT in first remission, optimal sequencing of transplant with novel therapies, and advancements in donor selection and conditioning regimens.<\/jats:p>","DOI":"10.1182\/hematology.2024000533","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:07:06Z","timestamp":1733497626000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Transplant in ALL: who, when, and how?"],"prefix":"10.1182","volume":"2024","author":[{"given":"Curtis","family":"Marcoux","sequence":"first","affiliation":[{"name":"1 Division of Hematology, Dalhousie University, Halifax, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"2 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"5","key":"2024121115362682600_hem2024000533C1","doi-asserted-by":"crossref","first-page":"100466","DOI":"10.1016\/j.modpat.2024.100466","article-title":"Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid\/lymphoid neoplasms with eosinophilia, dendritic\/histiocytic neoplasms, and genetic tumor syndromes","volume":"37","author":"Choi","year":"2024","journal-title":"Mod Pathol"},{"issue":"4","key":"2024121115362682600_hem2024000533C2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024121115362682600_hem2024000533C3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"issue":"17","key":"2024121115362682600_hem2024000533C4","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2024121115362682600_hem2024000533C5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41409-021-01253-6","article-title":"Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2024121115362682600_hem2024000533C6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41409-021-01262-5","article-title":"Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation","volume":"56","author":"Koller","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024121115362682600_hem2024000533C7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2024121115362682600_hem2024000533C8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood-2023-178150","article-title":"A multicenter analysis of allogeneic transplant outcomes in patients with Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL)","volume":"142","author":"Abdel Rahman","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024121115362682600_hem2024000533C9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"2024121115362682600_hem2024000533C10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2024121115362682600_hem2024000533C11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","article-title":"T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol","volume":"34","author":"Quist-Paulsen","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"2024121115362682600_hem2024000533C12","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study","volume":"35","author":"Bond","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024121115362682600_hem2024000533C13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"23","key":"2024121115362682600_hem2024000533C14","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience","volume":"5","author":"Richard-Carpentier","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2024121115362682600_hem2024000533C15","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood.2023021501","article-title":"Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"Suppl 2","key":"2024121115362682600_hem2024000533C16","first-page":"LBA","article-title":"Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024121115362682600_hem2024000533C17","first-page":"293","article-title":"Myeloid lineage switch in KMT2A- rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies","volume":"109","author":"Bataller","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"2024121115362682600_hem2024000533C18","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib- blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024121115362682600_hem2024000533C19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"2024121115362682600_hem2024000533C20","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024121115362682600_hem2024000533C21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115362682600_hem2024000533C22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","article-title":"Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2024121115362682600_hem2024000533C23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","article-title":"Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2024121115362682600_hem2024000533C24","doi-asserted-by":"crossref","first-page":"620.e621","DOI":"10.1016\/j.jtct.2021.03.026","article-title":"Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024121115362682600_hem2024000533C25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.22.00767","article-title":"Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115362682600_hem2024000533C26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2024121115362682600_hem2024000533C27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2021004916","article-title":"Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"6","author":"Wieduwilt","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115362682600_hem2024000533C28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"2024121115362682600_hem2024000533C29","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","article-title":"Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation","volume":"4","author":"Al Malki","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115362682600_hem2024000533C30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","article-title":"Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study","volume":"13","author":"Chang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2024121115362682600_hem2024000533C31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2024121115362682600_hem2024000533C32","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1002\/cncr.35004","article-title":"Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"129","author":"Giebel","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"2024121115362682600_hem2024000533C33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2024121115362682600_hem2024000533C34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"2024121115362682600_hem2024000533C35","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024121115362682600_hem2024000533C36","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024121115362682600_hem2024000533C37","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115362682600_hem2024000533C38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2024121115362682600_hem2024000533C39","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","article-title":"Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34- selected T-cell depleted allogeneic hematopoietic cell transplant","volume":"55","author":"Fabrizio","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2024121115362682600_hem2024000533C40","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2024121115362682600_hem2024000533C41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024121115362682600_hem2024000533C42","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2024121115362682600_hem2024000533C43","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024121115362682600_hem2024000533C44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"22","key":"2024121115362682600_hem2024000533C45","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2024121115362682600_hem2024000533C46","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"10299","key":"2024121115362682600_hem2024000533C47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2024121115362682600_hem2024000533C48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2024121115362682600_hem2024000533C49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"2024121115362682600_hem2024000533C50","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2024121115362682600_hem2024000533C51","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41409-020-0878-5","article-title":"Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia &gt;45 years undergoing allogeneic stem cell transplantation\u2014a retrospective study by the Acute Leukemia Working Party of EBMT","volume":"55","author":"Peric","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024121115362682600_hem2024000533C52","doi-asserted-by":"crossref","first-page":"95.e1","DOI":"10.1016\/j.jtct.2023.09.028","article-title":"Thiotepa-based regimens are valid alternatives to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"30","author":"Battipaglia","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2024121115362682600_hem2024000533C53","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1097\/HS9.0000000000000812","article-title":"Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of the EBMT","volume":"7","author":"Spyridonidis","year":"2023","journal-title":"Hemasphere"},{"issue":"4","key":"2024121115362682600_hem2024000533C54","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(22)00036-9","article-title":"In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"2024121115362682600_hem2024000533C55","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024121115362682600_hem2024000533C56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2024121115362682600_hem2024000533C57","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024121115362682600_hem2024000533C58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2024121115362682600_hem2024000533C59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"2024121115362682600_hem2024000533C60","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","volume":"8","author":"Metheny","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2024121115362682600_hem2024000533C61","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024121115362682600_hem2024000533C62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"2024121115362682600_hem2024000533C63","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2024121115362682600_hem2024000533C64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"30","key":"2024121115362682600_hem2024000533C65","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024121115362682600_hem2024000533C66","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2024121115362682600_hem2024000533C67","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry","volume":"27","author":"Cusatis","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/93\/2346803\/93marcoux.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/93\/2346803\/93marcoux.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:54:15Z","timestamp":1733946855000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/93\/526246\/Transplant-in-ALL-who-when-and-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000533","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}